智通财经APP获悉，野村发布研报称，维持石药集团(01093)“买入”评级，目标价由7.02港元下调至6.48港元。该行将石药2024财年收入及盈利预测分别下调1.2%及6.4%，主要考虑到集团去年首九个月的药品销售疲弱，以及1亿美元的预定许可收入。另外，该行亦将石药2025财年收入及盈利预测分别上调2.1%及0.8%。
野村表示，对石药2024财年的营收及盈利预测，较市场普遍预期低0.9%及0.8%;至于对2025财年的预测则高出0.1%及0.9%。该行亦指，理解石药在成熟业务方面面临压力，但认为公司最近对早期资产的对外授权部分，缓解了相关压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.